特異体質性薬物毒性の発現メカニズムに関する最近の知見

池田 敏彦

doi:10.1248/yakushi.14-00249-1

Animal experiments cannot predict the probability of idiosyncratic drug toxicity; consequently, an important goal of the pharmaceutical industry is to develop a new methodology for preventing this form of drug reaction. Although the mechanism remains unclear, immune reactions are likely involved in the toxic processes underlying idiosyncratic drug toxicity: the drug is first activated into a chemically reactive metabolite that binds covalently to proteins and then acts as an immunogen. Therefore, screening tests to detect chemically reactive metabolites are conducted early during drug development and typically involve trapping with glutathione. More quantitative methods are then used in a later stage of drug development and frequently employ ¹⁴Cor ³H-labeled compounds. It has recently been demonstrated that a zone classification system can be used to separate risky drugs from likely safe drugs: by plotting the amount of each protein-bound reactive metabolite in vitro against the dose levels in vivo, the risk associated with each drug candidate can be assessed. A mechanism for idiosyncratic drug-induced hepatotoxicity was proposed by analogy to virus-induced hepatitis, in which cytotoxic T lymphocytes play an important role. This mechanism suggests that polymorphism in human leukocyte antigens is involved in idiosyncrasy, and a strong correlation with a specific genotype of human leukocyte antigens has been found in many cases of idiosyncratic drug toxicity. Therefore, gene biomarkers hold promise for reducing the clinical risk and prolonging the life cycle of otherwise useful drugs.<br>

特異体質性薬物毒性の発現メカニズムに関する最近の知見

書誌事項

この論文をさがす

抄録

収録刊行物

被引用文献 (1)*注記

参考文献 (89)*注記

キーワード

詳細情報詳細情報について

書き出し

問題の指摘

特異体質性薬物毒性の発現メカニズムに関する最近の知見

書誌事項

この論文をさがす

抄録

収録刊行物

被引用文献 (1)*注記

参考文献 (89)*注記

キーワード

詳細情報 詳細情報について

書き出し

問題の指摘

詳細情報詳細情報について